PATIROMER SORBITEX CALCIUM | N205739 | VIFOR PHARMA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2020-01-23 | Terminated 2022-06-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Strides Pharma, Inc. FDA-2026-P-5017 · 3 docket documents Strides Pharma, Inc. filed this citizen petition requesting that the FDA determine whether VELTASSA (patiromer sorbitex calcium) oral powder under NDA 205739, held by Vifor Pharma Inc., was withdrawn from commercial distribution for safety or efficacy reasons or solely for commercial reasons. The pe | 505(q) | 2026-05-07 | Open | Strides Pharma, Inc. |
Citizen Petition from Hogan Lovells US LLP ( Relypsa Inc.) FDA-2017-P-4351 · 8 docket documents Relypsa Inc., through counsel Hogan Lovells US LLP, filed this citizen petition under 21 CFR Part 10.30 and section 505(o) of the FDCA on July 19, 2017, requesting that the FDA Commissioner require manufacturers of Kayexalate (sodium polystyrene sulfonate) and generic SPS products to add boxed warni | Other | 2017-07-20 | Withdrawn | Hogan Lovells US LLP ( Relypsa Inc.) |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$45.47
per ea
Lowest NADAC/Unit
$33.97
per ea
Brand NDCs
3
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 53436008404VELTASSA 8.4 GM POWDER PACKET | $45.47 | EA | Brand | — | 2026-06-17 |
| 53436008430VELTASSA 8.4 GM POWDER PACKET | $34.03 | EA | Brand | — | 2026-06-17 |
| 53436016830VELTASSA 16.8 GM POWDER PACKET | $33.97 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Code | Date | Status |
|---|---|---|
| NPP | Oct 2, 2026 | < 1 year |